Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Summary of Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2018 and December 31, 2017, and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value (in thousands):

	Fair Value Measurement at June 30, 2018
	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Cash equivalents	$	25,367	$	—	$	—	$	25,367
Total assets	$	25,367	$	—	$	—	$	25,367
Liabilities:
Indebtedness to Roche	$	—	$	110,000	$	—	$	110,000
Total liabilities	$	—	$	110,000	$	—	$	110,000

	Fair Value Measurement at December 31, 2017
	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Cash equivalents	$	25,183	$	—	$	—	$	25,183
Total assets	$	25,183	$	—	$	—	$	25,183
Liabilities:
Indebtedness to Roche	$	—	$	60,000	$	—	$	60,000
Total liabilities	$	—	$	60,000	$	—	$	60,000